openPR Logo
Press release

Antiviral nasal spray said to inactivate coronavirus in 1 minute

03-04-2021 11:08 AM CET | Health & Medicine

Press release from: The Harrington Post

MELBOURNE, Australia -- An antiviral nasal spray approved for European sale inactivates the coronavirus within one minute of use, the spray’s maker says.

Viraleze, available over the counter in Europe and the United Kingdom starting this month, is more than 99% effective in stopping the coronavirus, says Australian pharmaceutical company Starpharma Holdings Ltd., citing in-vitro studies paid for in part by the Australian government.

But the spray is meant to supplement COVID-19 vaccines, masks and other protective measures, not replace them, Starpharma says.

“If you are about to walk into the supermarket, you would use it,” says Starpharma Chief Executive Officer Jackie Fairley. “The same is true for public transport, elevators, planes, bars and restaurants.”

The spray is not absorbed into the bloodstream, she adds.

It can be stored at room temperature and requires no specialized transportation, the Melbourne company says.

Viraleze’s active ingredient is known as SPL7013, or astodrimer sodium.

When Viraleze is sprayed into the nose, the SPL7013 in it works by trapping “spike” proteins protruding from the surface of the coronavirus.

The nasal cavity is the main place where the coronavirus typically establishes itself before spreading to the lungs. The spike proteins, which look like a crown protruding from the outer edge of the virus, give coronaviruses their name.

Once the SPL7013 traps the proteins, “the virus is irreversibly blocked and can no longer infect mucosal cells, thereby providing a physical barrier to respiratory viruses in the nasal cavity,” Starpharma says in a statement.

The blocked coronavirus is then “eliminated naturally through the nasal mucus,” Starpharma says.

Without protection, the coronavirus spike proteins latch onto human cells, then change their physical structure to let the viral membrane fuse with the cell membrane. The coronavirus genes then enter the host cells and are copied, producing more viruses.

“SPL7013 has been shown to be virucidal, rapidly inactivating >99.9% of SARS-CoV-2 within 60 seconds,” Starpharma says. “SARS-CoV-2” is the formal name of the coronavirus that causes COVID-19.

The company did not say if SPL7013 was found to work equally well with coronavirus variants. Some new variants are more transmissible than the original and may be more infectious, studies indicate. They may also be less susceptible to some vaccines than the original coronavirus.

SPL7013 has broad antiviral action and Starpharma says it is also studying the possibility of using SPL7013 to help prevent the spread of HIV, the human papillomavirus and herpes viruses.

The Harrington Post
57 Fairmont Avenue
Kingston, New York 12401

Provider of healthcare and related news

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Antiviral nasal spray said to inactivate coronavirus in 1 minute here

News-ID: 2251821 • Views: 950

More Releases for Starpharma

Nanoengineered Prosthetics Market Analysis by Type, Application, Growth, Demand …
The latest competent intelligence report published by WMR with the title "An increase in demand and Opportunities for Global Nanoengineered Prosthetics Market 2022" provides a sorted image of the Nanoengineered Prosthetics industry by analysis of research and information collected from various sources that have the ability to help the decision-makers in the worldwide market to play a significant role in making a gradual impact on the global economy. The report
Agricultural Nanotechnology Market to Eyewitness Massive Growth by 2027 : Nanocy …
This Agricultural Nanotechnology Market report gives all around examination of parent market plans, gigantic degree financial pointers and controlling viewpoints nearby market offer as demonstrated by regions. The report besides maps the brand name aftereffect of grouped market viewpoints on market sections and topographies. Generally speaking factual looking over report 2021 that is a point-by-point impression a few perspectives, including the speed of progress, mechanical advances and different techniques executed
Vaginitis Therapeutics Market Size to 2026 : DARÉ BIOSCIENCE, INC, Hennepin Lif …
The market studies, insights and analysis encompassed in this comprehensive Vaginitis Therapeutics Market research report keeps marketplace clearly into the focus with which ladder of the success can be climbed easily. This report comprises market parameters ranging from industry outlook, currency and pricing, value chain analysis, market overview, premium insights, key insights to the company profile of the key market players. The Vaginitis Therapeutics Market document delivers with the best
Dendrimers and Polymer Drugs Conjugate Market Detailed Study Analysis with Forec …
Dendrimers, and polymer drug conjugates are nano–sized medicines used for therapeutic applications. In polymer drug conjugates, polymers are covalently bonded to the drug molecule and the linkers are biologically active. Dendrimers are highly water soluble, polyvalent, and have precise molecular weight. They act as carriers of drugs, and facilitate their administration in the body. Dendrimers also have other applications in diagnostic analyses, target therapy, and vaccines. They are also used
Future Analysis of the Bacterial Vaginosis Drugs Market Research Report Study By …
This report researches the worldwide Bacterial Vaginosis Drugs Market cover complete aggressive standpoint including the overall market, key trends, opportunities, and key statistics on the market status of the leading market players. The scope of the report extends from market scenarios to comparative pricing between major players, cost and profit of the specified market regions. Scope of the Report: Bacterial vaginosis is an imbalance of "good" and "bad" bacteria in the vagina,
Bacterial Vaginosis Global Key Players - Lupin Ltd, Starpharma Holdings Ltd, AmV …
Bacterial Vaginosis Overview Clinical trial report, “Bacterial Vaginosis Global Clinical Trials Review, H2, 2017" provides an overview of Bacterial Vaginosis clinical trials scenario. This report provides top line data relating to the clinical trials on Bacterial Vaginosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status,